Advertisement
Singapore markets open in 7 hours 31 minutes
  • Straits Times Index

    3,348.87
    +12.28 (+0.37%)
     
  • S&P 500

    5,252.85
    -24.66 (-0.47%)
     
  • Dow

    38,347.46
    -338.86 (-0.88%)
     
  • Nasdaq

    16,721.44
    -13.57 (-0.08%)
     
  • Bitcoin USD

    69,109.12
    +1,186.18 (+1.75%)
     
  • CMC Crypto 200

    1,443.34
    -24.60 (-1.68%)
     
  • FTSE 100

    8,262.75
    -12.63 (-0.15%)
     
  • Gold

    2,370.30
    +24.50 (+1.04%)
     
  • Crude Oil

    74.18
    -2.81 (-3.65%)
     
  • 10-Yr Bond

    4.4020
    -0.1120 (-2.48%)
     
  • Nikkei

    38,923.03
    +435.13 (+1.13%)
     
  • Hang Seng

    18,403.04
    +323.43 (+1.79%)
     
  • FTSE Bursa Malaysia

    1,596.68
    -7.58 (-0.47%)
     
  • Jakarta Composite Index

    7,036.19
    +65.46 (+0.94%)
     
  • PSE Index

    6,470.74
    +37.64 (+0.59%)
     

Psyence Biomed to Participate in the A.G.P. Virtual Healthcare Company Showcase

Psyence Biomedical Ltd.
Psyence Biomedical Ltd.

NEW YORK, May 17, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd (Nasdaq:PBM) (“Psyence Biomed” or the “Company”) today announced that management will host 1x1 meetings with investors during the A.G.P. Virtual Healthcare Company Showcase, which is being held May 21, 2024.

For more information, or to register: https://allianceg.com/events/.

About Psyence Biomed

Psyence Biomedical Ltd., a corporation organized under the laws of Ontario, Canada, is the world’s first life science biotechnology company traded on The Nasdaq Stock Market LLC (“Nasdaq”) (Nasdaq:PBM) that is focused on the development of botanical (nature derived, or non-synthetic) psilocybin-based psychedelic medicines. The name “Psyence” combines the words “psychedelics” and “science” to affirm Psyence Biomed’s commitment to an evidence-based approach to innovation as it works to develop safe and effective, nature-derived psychedelic therapeutics to treat a broad range of mental health disorders. Psyence Biomed is initially focused on mental health disorders in the context of Palliative Care.

ADVERTISEMENT

Learn more at www.psyencebiomed.com and on LinkedIn.

Contact Information
Email: ir@psyencebiomed.com
Media Inquiries: media@psyencebiomed.com
General Information: info@psyencebiomed.com
Phone: +1 416-477-1708

Investor Contact:
Jeremy Feffer
Managing Director
LifeSci Advisors
jfeffer@lifesciadvisors.com